Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.59 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.59 |
| ▸ | PRKX | P51817 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | PRKACA | P17612 | 3/20 | 0.59 |
| ▸ | PRKACG | P22612 | 3/20 | 0.59 |
| ▸ | PRKACB | P22694 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968116 | 1.00 | CYP3A4 (1.00) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL9398471 | 0.95 | CYP3A4 (0.90) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| Hydrochloric Acid SCHEMBL9780257 | 0.81 | LMNA (0.70) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL2712002 | 0.79 | L3MBTL1 (0.71) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL30366611 | 0.79 | CYP3A4 (0.65) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL17962258 | 0.78 | COMT (0.78) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL9397274 | 0.78 | CYP3A4 (0.64) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL2907389 | 0.78 | ROCK2 (0.67) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL2908180 | 0.78 | ROCK2 (0.67) | CYP3A4NFKB1TSHRTHPOHIF1A | |
| SCHEMBL2960623 | 0.78 | MEN1 (0.71) | CYP3A4NFKB1TSHRTHPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| US-20220313719-A1 | METHODS OF TREATING DISEASES ASSOCIATED WITH CHANGES IN PLATELET COUNTS USING PROTEIN KINASE A ACTIVATOR AND INHIBITOR | SOOCHOW UNIVERSITY (CN) | 2022-10-06 | — | — | US | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| US-20190343861-A1 | METHOD OF USING PROTEIN KINASE A ACTIVATOR AND INHIBITOR IN PREPARATION OF DRUGS FOR TREATING DISEASES ASSOCIATED WITH CHANGES IN PLATELET COUNTS AND FOR INHIBITING AND PROMOTING PLATELET APOPTOSIS | SOOCHOW UNIVERSITY (CN) | 2019-11-14 | — | — | US | claimed |
| CN-108339121-A | Application of protein kinase A inhibitor in preparation of medicines for treating diseases related to platelet increase | 苏州大学 | 2018-07-31 | — | — | CN | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | disclosed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-20220313719-A1 | METHODS OF TREATING DISEASES ASSOCIATED WITH CHANGES IN PLATELET COUNTS USING PROTEIN KINASE A ACTIVATOR AND INHIBITOR | SOOCHOW UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20190343861-A1 | METHOD OF USING PROTEIN KINASE A ACTIVATOR AND INHIBITOR IN PREPARATION OF DRUGS FOR TREATING DISEASES ASSOCIATED WITH CHANGES IN PLATELET COUNTS AND FOR INHIBITING AND PROMOTING PLATELET APOPTOSIS | SOOCHOW UNIVERSITY (CN) | 2019-11-14 | — | — | US | disclosed |
| CN-108339121-A | Application of protein kinase A inhibitor in preparation of medicines for treating diseases related to platelet increase | 苏州大学 | 2018-07-31 | — | — | CN | disclosed |
| US-5340811-A | Bronchodilator agent | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0471841-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | CYP3A4 1354/4885NFKB1 1153/4885TSHR 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.